Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
... Cell of data demonstrating potent anti-cancer activity
in colon and breast cancer models for the ... the risk for recurrence or more aggressive tumor activity
by increasing the ratio of cancer stem cells ... Moreover, OMP-21M18 displayed additive activity
in reducing tumor volume when combined with ...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
"ANA598 has demonstrated potent antiviral activity
and good tolerability as a single agent in Phase ... of ANA598 that have demonstrated potent antiviral activity
and good tolerability. In a monotherapy study in ... inhibitors. Furthermore, ANA598 retains full activity
in vitro against mutations conferring resistance ...
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
... has demonstrated promising anti-angiogenic activity
in preclinical studies. We are pleased to be ... MORPHODOMA((R)) technology, to improve the activity
of the antibodies or develop new antibodies for ... small molecule compound(s) with significant activity
minimizing solid tumors for cancer and ...
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
... a statistically significant decrease of epileptic activity
mice pre-treated with Kainic acid.
"We ... to abnormal, excessive or synchronous neuronal activity
brain. Epilepsy is one of the world's ... in the number of animals showing epileptic activity
and delayed the
onset of epileptic seizures.
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
... demonstrated sustained improvement in disease activity
and patient response rate through four years of ... associated with sustained improvement in disease activity
across multiple clinical measures, decreased ... improvement or stabilization of SLE disease activity
and with decreased frequency of SLE disease ...
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
... Data indicate target-dependent activity
in breast cancer patients with high expression of ... M. et al. (2009). Safety and anti-tumor activity
of 3-weekly anti-EpCAM antibody adecatumumab ... of MT203, a human antibody neutralizing the activity
of granulocyte/macrophage colony stimulating ...
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
... cells and tumor markers both suggest single-agent activity
warranting further clinical investigation.
The ... mg).
- No evidence of altered cardiac activity
- Majority of adverse events ... that strongly suggest single agent anti-cancer activity
for OGX-427," said Dr. Sebastien Hotte, Principal ...
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... has demonstrated inhibition of PI-3 kinase activity
at doses as low as 1 mg per patient.
"We are ... to assess the tolerability and pharmacodynamic activity
of both 24-hour and 72-hour infusions of PX-12. ... The compound has been shown to have anti-tumor activity
both as a single agent and in combination with ...
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
of Blinatumomab in NHL and ALL Highlighted at the ... (3) Sebastian et al. (2009). Safety and antitumor activity
of 3-weekly anti-EpCAM antibody adecatumumab ... is a traditional human antibody neutralizing the activity
of granulocyte/macrophage colony stimulating ...
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
... and Refractory CLL -- Early Promising Clinical activity
As of the abstract submission, 10 patients ... patients demonstrated evidence of biological activity
including high-risk patients. Two patients had ... the CD37 antigen and has shown potent anti-tumor activity
in pre-clinical studies. Trubion initiated a ...
Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
... on delafloxacin, one of which discusses the activity
and efficacy of delafloxacin in a Phase 2 ... The second poster session details the in vitro activity
of delafloxacin against a large, worldwide panel ... May 17, 1:30pm - Poster In vitro activity
of Topic 31: New
2009 2:30pm ...
UMass Boston Opens Venture Development Center to Expand R&D Activity
... expand the university's research and development activity
and provide entrepreneurial opportunities for ... to the Dorchester waterfront."
at UMass Boston has increased at a rate nearly ... the past five years. This expansion in research activity
is helping to grow UMass Boston's role as an ...
Telik Reports Preclinical Results at AACR Annual Meeting
... and carcinogenesis. Inhibition of Aurora kinase activity
induces growth arrest and apoptosis in cells and ... Drug inhibition of aurora kinase and VEGFR activity
in tumor samples of treated animals was ... vivo, TLK58747 demonstrated significant antitumor activity
both orally and parenterally against a wide ...
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
... HCV patients that demonstrated potent antiviral activity
over three days," said Steve Worland, Ph.D., ... sites.
Potent Antiviral activity
in HCV. Earlier today, Anadys presented ... in a late-breaker poster entitled, "Antiviral activity
of ANA598, a Potent Non-Nucleoside Polymerase ...
Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
... has demonstrated increased antiviral activity
when tested in combination with HCV protease ... Protease Inhibitor
IDX316 exhibited potent activity
against HCV NS3/4A proteases from multiple ... with tight binding to the HCV protease and no activity
observed against eight human cellular proteases. ...
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
... absence of interferon, result in robust antiviral activity
in treatment-naive HCV patients. INFORM-1 has ... to evaluate the safety and combined antiviral activity
of ITMN-191 and R7128 in 14 days of combination ... to evaluate the safety and combined antiviral activity
of R7227 (ITMN-191), a protease inhibitor, and ...
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
... the safety data as well as the promising clinical activity
observed in this trial, Poniard initiated a ... regimen; both regimens have similar anti-tumor activity
in first-line metastatic CRC. We are continuing ... drugs. Picoplatin has demonstrated anti-tumor activity
in a variety of solid tumors. It is being studied ...
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
... pipeline to demonstrate broad anti-cancer activity
in pre-clinical models, including synergy with ... death (apoptosis) in tumor cells by blocking the activity
of at least three "inhibitors of apoptosis ... the cancer cell. AT-406 is thought to mimic the activity
of Smac (second mitochondria-derived activator of ...
AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
-- One study, to determine whether the superior activity
of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity
that may not have been seen with the less ... The study determined that the increased target activity
and cytotoxicity of DXL-modified anti-CD20 does ...
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
... (1) demonstrating the potent anti-tumor activity
of a BiTE antibody binding to carcinoembryonic ... shows that novel BiTE antibodies have strong activity
against CEA-expressing cancer cells in vitro and ... may not pose a limitation for the anti-tumor activity
of BiTE antibodies."
MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
... Technology enhances biological activity
(regenerative potential) of stem cells and ... technology for customizing the biological activity
of cells for therapeutic use. This system, which ... ability to customize and enhance biological activity
of cells and ensure robust product ...
Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
... of over 250,000 new molecular entities with activity
for a broad spectrum of infectious diseases. Orally bioavailable with excellent single-drug activity
against Mycobacterium tuberculosis in vitro and in vivo , SQ609 has demonstrated synergistic activity
with several front-line antitubercular drugs and ...
Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203
... that optimize or augment the therapeutic activity
of antibodies, and one important technology ... in development demonstrating enhanced anti-tumor activity
in xenograft models, even with single doses as ... studies have also demonstrated that anti-tumor activity
is maintained in drug-resistant cancer cells. ...
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
... reports that in the 2008-2009 season, influenza activity
increasing rapidly across Europe. The first countries to report high
intensity of influenza activity
were Portugal and Ireland. To date, medium or
high intensity activity
has been reported in nineteen countries.(1) Of ...
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
... that both regimens have similar anti-tumor activity
in first-line metastatic CRC. Net sales in 2007 ... FOLPI regimen, but manageable.
also was similar in the FOLPI and FOLFOX groups. ... than 750 patients and has demonstrated anti-tumor activity
in multiple indications with less severe kidney ...
First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
... drug conjugate that
has demonstrated therapeutic activity
in patients. In addition to the Phase 2
clinical ... profile that has
demonstrated therapeutic activity
Positive Phase 1 data for ... highlighted the compound's significant anti-tumor activity
superior pharmacokinetic profile. Patients ...
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
... R7128's higher barrier to resistance and activity
across multiple viral genotypes, as well as the ... of that molecule. R7128 has shown in vitro activity
against all of the most common HCV genotypes (1, ... demonstrated significant short-term antiviral activity
with safety and tolerability comparable to ...
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
... and R-Amphinase (R-Amph) show anti-tumor activity
in chronic lymphocytic leukemia (CLL) and acute ... cell line. These reports now broaden ONCONASE's activity
into CLL and AML, and include a related ... 72 hours of treatment, respectively. Synergistic activity
was seen in the combination of the endonuclease ...
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
product, carfilzomib, has single-agent activity
and promotes durable responses
in patients with ... Myeloma Research Consortium (MMRC).
in Relapsed and Refractory Multiple Myeloma ... Myeloma (MM)
in Relapsed Patients by Prior Exposure to ...
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
tolerability, pharmacodynamic effects and activity
of ENMD-2076 in this
... in vitro indicated synergistic
towards several human multiple myeloma cell ... B. ENMD-2076 has
shown significant cytotoxic activity
preclinically towards a variety of human
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
... Demonstrates Proteasome Inhibition and Anti-Tumor activity
SOUTH SAN FRANCISCO, Calif., Dec. 8 ... evaluated PR-047's mechanism, bioavailability and activity
in a series of preclinical studies. Like ... PR-047 was shown to target the chymotrypsin-like activity
of the proteasome and induce tumor cell death ...
BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System
... body-monitoring products can measure physical activity
and calories burned with BodyMedia's level of ... upper left arm;
o An Online activity
Manager - which allows users to set and track ... for $199. Subscription rates for the Online activity
Manager are between $6.95/month and $12.95/month, ...
/C O R R E C T I O N -- Rosetta Genomics Ltd/
... Since many diseases are
caused by the abnormal activity
of proteins, the ability to selectively
regulate protein activity
through microRNAs could provide the means ... Since many diseases are
caused by the abnormal activity
of proteins, the ability to selectively
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
... the Phase 2 Program
Entitled, "The antitumoral activity
and safety of AEZS-108 (AN-152), a
LHRH agonist ... in a
clinical study that targets the cytotoxic activity
specifically to LHRH-receptor expressing tumors. Finally, signs of
were observed in 7 out of 13 patients treated ...
Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
... Metabolic effects such as glucose lowering activity
combination of insulin plus rHuPH20 were ... shifts insulin exposure and glucose
to earlier times and away from late postprandial times,
insulin kinetics and activity
for the combination of insulin plus rHuPH20
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
... from preclinical
studies that demonstrate the activity
of ceftaroline against
methicillin-resistant ... was
completed and ceftaroline demonstrated activity
against a broad range of
gram-positive pathogens ... / IDSA include the
tested against organisms causing skin and ...
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
... following properties:
- Stronger anti-HCV activity
in fresh human hepatocytes infected with HCV ... than IFN alpha 2 drugs.
- Stronger anti-HCV activity
in vitro in the HCV genotype 1b subgenomic ... GEA007.1 exhibits a 7 fold superior inhibitory activity
on HCV genotype 1b RNA synthesis compared to IFN ...
Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
... and highlighted the
significant anti-tumor activity
and superior pharmacokinetic profile of
NKTR-102. ... University of
Arizona. "Additionally, the drug's activity
in a number of tumor types,
particularly in ... the safety, pharmacokinetics and
of NKTR-102 monotherapy was evaluated in 57 ...
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
... ENMD-2076 is a novel kinase inhibitor with potent activity
Aurora A and a number of tyrosine kinases ... a substantial decrease in
tumor metabolic activity
in animals treated with ENMD-2076.
ENMD-2076 ... mechanisms of action,
including antiproliferative activity
and the inhibition of angiogenesis.
ENMD-2076 has ...
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
... that both
regimens have similar anti-tumor activity
in first-line metastatic CRC.
"Picoplatin ... Society of Clinical Oncology in May.
also was found to be similar in the FOLPI ... than 750 patients and has
demonstrated anti-tumor activity
in multiple indications with less severe